OOIR: Observatory of International Research

Papers

(The H4-Index of European Respiratory Journal is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
The right ventricle tamed	1600
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	1038
Chymase-1: a “MAST”-er switch in COPD?	342
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	301
Missing airways, ventilation defects and conductive airway physiology in asthma	217
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	205
A breath of the future: a novel human model for COPD and beyond	196
The lung that rules the heart	180
Randomised controlled trials utilisingF_ENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	145
Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?	138
From spatial transcriptomics to mouse model: the (re-)emergence of ductal myofibroblasts as a new cellular target in idiopathic pulmonary fibrosis	137
Novel pathomechanisms of ventilator-induced neonatal lung injury: new targets to overcome ongoing challenges	132
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	129
Gene–environment interaction at 17q12–q21 locus and its role in asthma pathogenesis	125
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	124
Soteria: deliverance from harm?	120
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	120
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	117
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	116
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	112
sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension	109
Associations between High-Density Lipoprotein Cholesterol and Interstitial Lung Abnormalities in the Korean National Lung Cancer Screening	103
Shear-wave elastography-guided transthoracic biopsy for lung lesions: a randomised controlled trial	103
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	102
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	102

Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	98
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	96
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	94
A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease	94
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	91
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	91
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	91
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	90
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	87
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	86
Pulmonary hypertension associated with hereditary haemorrhagic telangiectasia: from genetics to clinical management	84
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	81
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	81
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	80
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	77
Antiviral CD8⁺T-cell immune responses are impaired by cigarette smoke and in COPD	75
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	72
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	71
Treatment algorithm for pulmonary arterial hypertension	71
No exposure left behind: time to pay attention to children's chemical environment in lung development	70
The impact of oral anticoagulants on idiopathic pulmonary fibrosis risk and prognosis: a population study	68
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment	67
Exciting times for trimodulin	66
Challenges in harmonising terms and patterns among interstitial pneumonias: enter idiopathic bronchiolocentric interstitial pneumonia	65
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis	64
The limits of normal of pulmonary arterial wedge pressure	63
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?	63
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough	62
Reply: Tuberculosis screening in migrants to the EU/EEA and UK	62
Pleural mesothelioma: surgery questioned again?	61
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?	59
List ofEuropean Respiratory Journalpeer reviewers 2023	58
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension	57
Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain	57
CPAP recall and cancer risk: should we be concerned?	57